Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia ...
| MDCX Stock | USD 2.81 0.14 5.24% |
Slightly above 55% of Medicus Pharma's investors are presently thinking to get in. The analysis of overall sentiment of trading Medicus Pharma Ltd otc bb equity suggests that some investors are interested at this time. Medicus Pharma's investing sentiment can be driven by a variety of factors including economic data, Medicus Pharma's earnings reports, geopolitical events, and overall market trends.
Medicus |
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma Currently Underway in United States TORONTO, Dec. 02
Read at gurufocus.com
 |
Medicus Pharma Fundamental Analysis
We analyze Medicus Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicus Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicus Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Medicus Pharma is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Medicus Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Medicus Pharma otc bb equity to make a market-neutral strategy. Peer analysis of Medicus Pharma could also be used in its relative valuation, which is a method of valuing Medicus Pharma by comparing valuation metrics with similar companies.
Peers
Medicus Pharma Related Equities
| ADI | Analog Devices | 1.91 | ||||
| NTGR | NETGEAR | 1.56 | ||||
| SCWTF | Schweiter Technologies | 0.00 | ||||
| PSFE | Paysafe | 1.04 | ||||
| MARIF | Marimaca Copper | 1.04 | ||||
| LOMLF | Lion One | 4.55 |
Additional Tools for Medicus OTC BB Equity Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.